🔗 Share this article

While the United States proceeds with sweeping revisions to its immunization recommendations, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has concentrated on possible fatalities following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Program

Public health authorities had intended to unveil sweeping changes to the childhood vaccine schedule recently, aligning the US with the Danish vaccine program, according to reports – a significant shift that would place the US out of alignment with much of the global community with insufficient data for improved outcomes. The announcement has been pushed back until the next year.

Rather than Vinay Prasad, Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the division this year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric vaccine recommendations in the US in order to be more like Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Background

Høeg has little discernible track record in pharmaceutical research, regulation or administrative roles, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a large organization. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that former directors who led the center have had.”

This division has an vast workload at the FDA, the former commissioner emphasized.

“Many people just focuses on the novel medication approvals, but the generic drug division clears thousands of generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and each of these need to be managed,” she said. “The area you overlook, that is the part that I always told people is going to bite you.”

There is also, a substantial leadership component to the role, which oversees over 5,000 personnel. “It is a enormous administrative position, if you perform it correctly,” Woodcock said.

Official Statement and Controversial Policies

In response to concerns about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a representative stated that the “concerns are based on inaccurate assumptions”.

“Her experience matches the responsibilities of her position,” the representative stated, citing the months Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's new fast-track approval initiative, a controversial expedited medication authorization process that apparently worried her former heads. “How are these medications being chosen for this voucher program? Who takes the decisions?” Howard said. “There’s a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards laxer regulations of pharmaceuticals, aside from shots.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a more documented, if troubling, past, some experts have noted. She authored a study using unverified crowd-sourced reports to determine the frequency of myocarditis after COVID-19 vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are riskier than they are.

Among her “wish list” for the new federal leadership included changing rules for novel immunizations and halting “unnecessary” immunizations, she stated post-election on a online show. At the FDA, Høeg has reportedly proposed preventing adolescent males from getting Covid vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and works backwards to retrofit the data in a highly misleading, untruthful manner,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|